维普中文期刊产品整合服务
5篇 您的检索式:作者名="Zankhana"
    题名 作者 年代 出处 被引量
1Cardiovascular Risk Assessment of the Liver Transplant Candidate显示文摘Zankhana Raval Matthew E. Harinstein Anton I. Skaro Ata Erdogan Andre M. DeWolf Sanjiv J. Shah Oren K. Fix Nina Kay Michael I. Abecassis Mihai Gheorghiade James D. Flaherty 2011Journal of the American College of Cardiology2011,,3:1
2The microRNA-30 Family Is Required for Vertebrate Hepatobiliary Development显示文摘Nicholas J. Hand Zankhana R. Master Steven F. Eauclaire Daniel E. Weinblatt Randolph P. Matthews Joshua R. Friedman 2009Gastroenterology2009,,3:1
3The microRNA-30 Family Is Required for Vertebrate Hepatobiliary Development显示文摘Nicholas J. Hand Zankhana R. Master Steven F. Eauclaire Daniel E. Weinblatt Randolph P. Matthews Joshua R. Friedman 2009Gastroenterology2009,,3:1
4Cardiovascular Risk Assessment of the Liver Transplant Candidate显示文摘Zankhana Raval Matthew E. Harinstein Anton I. Skaro Ata Erdogan Andre M. DeWolf Sanjiv J. Shah Oren K. Fix Nina Kay Michael I. Abecassis Mihai Gheorghiade James D. Flaherty 2011Journal of the American College of Cardiology2011,,3:1
5Role of cardiovascular intervention as a bridge to liver transplantation显示文摘End stage liver disease(ESLD) is associated with many specific derangements in cardiovascular physiology, which influence perioperative outcomes and may pro-foundly influence diagnostic and management strate-gies in the preoperative period. This review focuses on evidence-based diagnosis and management of coro-nary, hemodynamic and pulmonary vascular disease in this population with an emphasis on specific strategies that may provide a bridge to transplantation. Specifi-cally, we address the underlying prevalence of cardio-vascular disease states in the ESLD population, and relevant diagnostic criteria thereof. We highlight tradi-tional and non-traditional predictors of cardiovascular outcomes following liver transplant, as well as data to guide risk-factor based diagnostic strategies. We go on to discuss the alterations in cardiovascular physiology which influence positive- and negative-predictive values of standard noninvasive testing modalities in the ESLD population, and review the data regarding the safetyand efficacy of invasive testing in the face of ESLD and its co-morbidities. Finally, based upon the totality of available data, we outline an evidence-based ap-proach for the management of ischemia, heart failure and pulmonary vascular disease in this population. It is our hope that such evidence-driven strategies can be employed to more safely bridge appropriate candidates to liver transplant, and to improve their cardiovascular health and outcomes in the peri-operative period.Zankhana Raval Matthew E Harinstein James D Flaherty 2014World Journal of Gastroenterology2014,20,31:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费